|
|
|
|
|
|
|
|
|
|
|
|
|
|
Previous: KERYX BIOPHARMACEUTICALS INC, S-1/A, EX-23.3, 2000-06-29 |
Next: KERYX BIOPHARMACEUTICALS INC, 8-A12G, 2000-06-29 |
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the audited
consolidated financial statements at December 31, 1999 and for the year then
ended and from the condensed consolidated financial statements at March 31, 2000
and for the three month period then ended, and is qualified in its entirety by
reference to such financial statements.
</LEGEND>
<S> <C> <C>
<PERIOD-TYPE> 12-MOS 3-MOS
<FISCAL-YEAR-END> DEC-31-1999 DEC-31-2000
<PERIOD-START> JAN-01-1999 JAN-01-2000
<PERIOD-END> DEC-31-1999 MAR-31-2000
<CASH> 4,126,735 6,551,344
<SECURITIES> 0 0
<RECEIVABLES> 0 0
<ALLOWANCES> 0 0
<INVENTORY> 0 0
<CURRENT-ASSETS> 4,378,557 6,873,225
<PP&E> 217,337 233,895
<DEPRECIATION> 57,196 64,505
<TOTAL-ASSETS> 4,948,216 7,606,857
<CURRENT-LIABILITIES> 394,417 404,690
<BONDS> 0 0
0 0
79 118
<COMMON> 1,208 1,208
<OTHER-SE> 4,434,776 7,071,681
<TOTAL-LIABILITY-AND-EQUITY> 4,948,216 7,606,857
<SALES> 0 0
<TOTAL-REVENUES> 0 0
<CGS> 0 0
<TOTAL-COSTS> 0 0
<OTHER-EXPENSES> (8,992,792) (1,811,847)
<LOSS-PROVISION> 0 0
<INTEREST-EXPENSE> 0 0
<INCOME-PRETAX> (8,992,792) (1,811,847)
<INCOME-TAX> 9,970 27,121
<INCOME-CONTINUING> 0 0
<DISCONTINUED> 0 0
<EXTRAORDINARY> 0 0
<CHANGES> 0 0
<NET-INCOME> (9,002,762) (1,838,968)
<EPS-BASIC> (1.67) (0.34)
<EPS-DILUTED> (1.67) (0.34)
</TABLE>
|
|